Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Indication

Liver Cancer

Clinical and regulatory intelligence for Liver Cancer with 5 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals
5
Catalysts
0
Assets
2

Relevant assets

Innovation →
Oncology →

Relevant companies

No related entities indexed yet.

Recent signals(5)

RegulatoryAugust 5, 2026

Innovation Passports Granted for Liver Cancer and Dementia Products

The Innovative Licensing and Access Pathway has granted Innovation Passports to investigational products targeting liver cancer and dementia.

ClinicalJuly 4, 2026

Study on 188Re-SSS Lipiodol SIRT for Non-Operable Liver Cancer Initiated

A monocentric interventional study is underway to evaluate the efficacy of 188Re-SSS lipiodol selective internal radiation therapy (SIRT) in patients with non-operable hepatocellular carcinoma (HCC).

ClinicalJuly 3, 2026

Study on AKI Prevention in Liver Cancer Patients Undergoing Therapy

A study is underway to develop an AKI risk prediction model and assess proactive nursing interventions for liver cancer patients.

ClinicalJune 27, 2026

Study Reveals Impact of Blood Flow on Microwave Ablation Efficacy

The study introduces the Antenna-Blood flow Relative Angle (ABRA) to assess how blood flow direction and velocity affect ablation zone geometry.

ClinicalJune 2, 2026

Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial

The EMERALD-3 Phase III trial demonstrated a statistically significant improvement in progression-free survival for Imfinzi plus Imjudo in patients with unresectable liver cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Therapeutic areas

Dementia →
Liver Cancer →
Liver Cancer, Neurology →
Oncology →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.